down 8% on a 2.5% miss. makes sense.
This is one of the many reactions I can't figure out. What's good in the report to make the stock move higher?
Waiting for this one to "break out" is like watching a snail cross a sidewalk and hoping it starts to run. Nevertheless, I'm long.
then you should short it. although, with your kind of insight, you probably shorted when it hit $475.
the support last week was amazing. this bounce was pretty predictable.
seriously? when have earnings mattered to development-stage biotechs? it's about the pipeline.